Synaptogenix, Inc. operates as a biopharmaceutical company. It develops a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease, which is in the clinical testing stage. The firm also evaluates potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions. The company was founded on October 31, 2012 and is headquartered in New York, NY.
Don’t forget to vote on your own request @MartianAce
Also make sure you’ve filled out the details here
1 Like